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INTRODUCTION 
 The Ocular Surface System includes the surface and glandular epithelia of 
the cornea, conjunctiva, lacrimal land accessory lacrimal glands, meibomian gland, 
eyelashes with their associated glands of Moll and Zeis, and the nasolacrimal duct.
1
 
 Disruption of the function ocular surface structures may result in ocular 
surface disorders. Treatment for ocular surface disorders includes artificial tears 
substitutes, temporary or permanent punctal occlusion, bandage contact lenses, and 
primary treatment of adnexal diseases.  
 Ocular surface disorder is most commonly treated with artificial tear eye 
substitute. Commercially available artificial tear preparation does not include 
essential tear components such as growth factors, vitamins, and immunoglobulins. 
Artificial tear substitute often contains preservatives, stabilizers, additives, which 
can induce toxic or allergic reactions.
2
 
 Recently autologous serum eye drops is routinely prescribed as an adjuvant 
therapy for the treatment ocular surface disorders, like dry eye disorders, 
neurotrophic keratitis, recurrent corneal erosion, persistent epithelial defects.
3-5
 
Human serum apart from providing lubrication, it contains substances such as 
EGF, vitamin A, TGF-β, fibronectin and interleukins, which are normally found in 
tears. They are essential for corneal &conjunctival epithelial healing and integrity.
4
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APPLIED ANATOMY 
 
THE OCULAR SURFACE SYSTEM  
 Maintenance and protection of the smooth refractive surface of the cornea is 
the function of the Ocular Surface System. 
 
The Ocular Surface System contains 
 Surface and glandular epithelia of the cornea and conjunctiva, 
 Lacrimal gland and accessory lacrimal glands, 
 Meibomian gland, and their apical (tears) and basal (connective tissue) 
matrices,  
 Glands of Moll and Zeis,  
 Nasolacrimal duct.1 
  
The Ocular Surface System encompasses different ocular structures. They 
are brought the name “Ocular Surface System” because 
 All components are derived from the surface ectoderm 
 They are linked by continuity of the epithelia,  
 They are controlled by common innervations, and by the endocrine     
systems. 
3 
 
 
 They function synchronously to provide, protect and maintain a smooth 
refractive ocular surface
6
. 
 
 Sagittal section through the ocular surface system is depicted below (Fig 1). 
It shows the continuity of the ocular surface epithelium (in pink) with regional 
specializations. Blue line depicts the pre ocular tear film. 
 
Fig 1 
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LACRIMAL FUNCTION UNIT 
 It includes the ocular surface system along with the sensory and motor 
innervations which act together and not in isolation
7
. 
 
TEAR FILM 
 Tear film is a complex fluid mixture, essential for protecting, nourishing, 
and maintaining the health of the ocular surface.  
 
The tear film contains the secretions of the  
 lacrimal gland, 
 accessory lacrimal glands of Krause and Wolfring,  
 meibomian glands,  
 glands of Zeis and Moll,  
 conjunctival goblet cells, 8, 9. 
 
The lacrimal system can be divided functionally into two parts:  
 Basal secretors (goblet cells, accessory lacrimal glands of Krause and 
Wolfring, , and meibomian, Zeis& Moll glands)  
 Reflex secretors (the lacrimal gland) 10. 
 
5 
 
Glands contributing to the tear film are described briefly below. 
 
LACRIMAL GLANDS 
 The lacrimal gland is a tubulo-alveolar gland of serous type. It is located in 
the superolateral part of the orbit, immediately behind the orbital rim within the 
lacrimal fossa of the frontal bone (Fig 2). It is divided into an upper (orbital) and 
lower (palpebral) lobe by the lateral horn of the levator aponeurosis.  
 
      Fig 2 
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Blood Supply  
 Supplied by lacrimal artery. 
  Transverse facial artery also occasionally supplies the gland.  
 Lacrimal veins drain the lacrimal glands and they join the ophthalmic 
veins
11
. 
Nerve Supply  
 Sensory Nerve Supply is by ophthalmic nerve, first division of 
Trigeminal nerve (Fig 3) 
  Sympathetic nerve supply is by the cervical sympathetic plexus 
around the carotid artery 
 Parasympathetic fibres from Superior salivatory nucleus, stimulates 
tear secretion.
10
 
      Fig 3 
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ACCESSORY LACRIMAL GLANDS 
 Glands of Krause: They are situated in the palpebral conjunctiva 
between fornix and the edge of tarsus (Fig 4). They are more in the 
upper fornix than the lower fornix.  
 Glands of Wolfring: They are located near the upper margin of the 
superior tarsal plate and along the  inferior border of the tarsal plate of 
the lower lid.
11
 
 Rudimentary Accessory Lacrimal Gland: These are present in 
caruncle plica semilunaris and interorbital region. 
       
Fig 4 
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CONJUNCTIVAL GOBLET CELLS 
 They are mucin-secreting glands present in the conjunctiva. They secrete in 
response to the parasympathetic nerve stimulation
12
. 
MEIBOMIAN GLANDS 
 They are modified sebaceous glands situated in the tarsal plates. It consists 
of multiple acini, which drains through a central duct. They synthesize lipids 
(meibum) which form the outer layer of tear film
13
. 
 
Fig 5 
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GLANDS OF ZEIS 
 These are modified sebaceous glands that are associated with lash follicles. 
 
GLANDS OF MOLL 
 These are modified apocrine sweat glands which open either into a lash 
follicle or directly onto the anterior lid margin between the lashes.
12
 
  
LAYERS OF TEAR FILM 
     Tear film has three layers (Fig 6), outer lipid layer (0.1 μm thick), aqueous layer 
(7-10 μm thick) in the middle, and inner mucinous layer (0.2-1.0 μm thick).14, 15 
 
1. Mucin Layer 
 Microplicae and microvilli present in superficial epithelial cells of 
cornea and conjunctiva are essential for the even distribution of this mucin 
layer. This layer is secreted by goblet cells of the conjunctiva (Fig 7). It 
helps to lubricate the ocular surface and to trap and eliminate foreign 
matter. It stabilizes the tear film. 
 
 
 
10 
 
2. Aqueous layer 
Main and accessory lacrimal glands contribute to the aqueous layer. It 
constitutes the main bulk of tear film. Aqueous layer supplies oxygen to 
the corneal epithelium and clears the debris and irritants and it also 
contains anti bacterial sub-lysozyme & betalysin. 
 
Fig 6 
 
 
3. Lipid layer 
Outermost superficial lipid layer is derived from the secretions of 
Meibomian, Zeis and Moll glands. It measures only 0.1 μm.16 It prevents 
evaporation of the tear film.
17 
It helps in preventing tear spillage from the 
11 
 
ocular surface. It also prevents eyelid skin damage by tears, and forms a 
protective seal over the ocular surface during sleep.
18
 
   
Fig 7 
 
 
 
COMPONENTS IDENTIFIED IN THE TEAR FILM 
 Water content 
 Proteins like albumin, immunoglobulin, lactoferrin, alpha-1anti trypsin and 
beta 2 microglobulins, mucopolysaccharides, glycoprotein, amino acids, 
alpha-1 anti chymotrypsin. 
12 
 
 Enzymes are lysozyme, glycolytic enzyme, lactate dehydrogenase, beta 
lysine 
 Metabolites are glucose, lactate, pyruvate, urea 
 Electrolytes - potassium, calcium11 
 
EPIDEMIOLOGY 
Dry eye is more prevalent amongst the elderly, particularly postmenopausal 
females.
19
 
 
Major Epidemiologic Studies of Dry-Eye Disorders in the USA 
Nurses Health Study (Schaumberg et al) shows prevalence of 5.7% less than 
50years and 9.8% in more than 75 yrs old whereas Salisbury Maryland Study 
shows prevalence of 14.6% and similarly Beaver Dam eye study shows 14.4% 
prevalence.
20, 21
 
DE in India:  
There are no published reports on the prevalence of DE in South India. In 
North and East Indian population the prevalence of 18.4% to 40.8% in hospital 
based population.
22, 23
A higher prevalence of 54% in high altitude population is 
noted in a study.
24
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OCULAR SURFACE DISORDERS 
 
 Ocular surface disorders include conditions causing defective production, 
altered composition, or distribution of tear film which may result in damage to the 
ocular surface.
19 
 
 Ocular surface disorders can be classified into Dry eye disease and Non dry 
eye disease
25
. 
Fig 8 
 
14 
 
DRY EYE  
 Dry eye syndrome (DES) is multifactorial disease of the tears and ocular 
surface, which results in symptoms of discomfort, visual disturbance and tear film 
instability with potential damage to the ocular surface. It is accompanied by 
increased osmolarity of the tear film and inflammation of the ocular surface. 
  
Dry eye disease is further sub classified into  
 1. Aqueous Deficient Dry Eye (ADDE) 
 2. Evaporative Dry eye (EDE) 
 
1. Aqueous deficient dry eye,  
 It is due to a failure of secretion of lacrimal tears. It is divided into two sub 
categories viz, Sjögren’s Syndrome Dry Eye and non-Sjögren’s Syndrome Dry 
Eye.  
a. Sjögren’s syndrome Dry Eye (SSDE) 
It is the auto immune disease of the exocrine glands, in which the 
lacrimal and salivary glands, and other organs, are targeted by an 
autoimmune disease
25
.  
15 
 
Primary Sjögren’s Syndrome occurs in the absence of other discrete 
autoimmune diseases.
20 
Secondary Sjögren’s Syndrome occurs with an overt 
autoimmune connective disease, most commonly rheumatoid arthritis.  
It presents with dry eyes, dry mouth, and evidence of an autoimmune 
disease. 
Objective findings necessary for the diagnosis of ocular features of 
Sjögren’s syndrome are, 
 Absence of nasal-lacrimal reflex tearing 
 Evidence of dry eye disorder and decreased tear break up time by 
ocular surface dye staining 
 Serological detection of auto antibodies. 
.Diagnosis 
i. Serologic tests 
o antinuclear antibody (ANA),  
o Specific antibodies (ie, anti-Ro [SS-A], anti-La [SS-B]). 
o Anti Rheumatoid factor Antibody for Secondary Sjogren’s 
syndrome 
 
16 
 
ii.   Biopsy from lacrimal glands & accessory salivary glands  
iii. Impression cytology of buccal mucosa
26
. 
 
b. Non Sjögren’s Syndrome Dry Eye (Non SSDE) 
 Non-SSDE is a form of aqueous deficient dry eye, where systemic 
autoimmune features of SSDE have been excluded
27
. Causes of Non SSDE are 
listed below. 
1. Age related hyposecretion of lacrimal gland 
2. Lacrimal tissue destruction (tumour, sarcoidosis) 
3. Absence or reduction of lacrimal gland tissue. 
4. Conjunctival scarring and obstruction of lacrimal gland ductules. 
i. Cicatrical pemphigoid 
ii. Stevens - Johnson syndrome 
iii. Chemical burns 
iv. Long standing trachoma 
5. Reflex hypo secretion due to sensory or motor block,  
6. Systemic drugs -beta-blockers, antihistamines.12  
 
 
17 
 
Steven Johnson’s Syndrome 
 It is mucocutaneous vesiculo bullous disease 
 It is due to acute vasculitis affecting conjunctiva and other mucus 
membrane 
 Most common drugs are Sulfa drugs (Acetazolamide), Penicillin, 
Barbiturate, and Salicylate. 
 Membranous muco-purulent conjunctivitis leading to scarring of 
conjunctiva (Fig 9) and lid margin resulting in destruction of 
Meibomian glands, conjunctival goblet cells and limbal stem cells. 
Fig 9 
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2. Evaporative dry eye 
It is due to excessive water loss from the exposed ocular surface  
Intrinsic Evaporative Dry Eye  
Intrinsic evaporative eye disease is due to  
 Meibomian gland dysfunction, (Meibomitis)  
 Lid abnormality and poor lid dynamics 
 Ocular side effects due to systemic retinoids 
Extrinsic Evaporative Dry Eye 
 Side effects due to toxic topical agents such as preservatives,  
 Ocular surface diseases, including allergic eye disease. 
 Deficiency of Vitamin A  
 Contact lens wear27 
 
Meibomian Keratoconjunctivitis. 
 It is the most severe lid margin inflammation. 
 It is mostly associated with rosacea.  
19 
 
 Clogging of the meibomian gland opening with desquamated 
epithelial cells causes inflammation.
19
 
 
Fig 10 
 
 
Meibomian gland evaluation 
 By microscopic evaluation of ductal orifice, gland turbidity and 
viscosity. 
 Meibography 
 Meibometry 
 
 
 
20 
 
CLINICAL SYMPTOMS & SIGNS OF DRY EYE 
•Mild DE:  
o Irritation, itching,  
o Soreness, burning, 
o Foreign body sensation 
o Blurring of vision. 
o Photophobia 
o Stingy discharge 
Due to innocuous symptoms and minimal clinical signs and inconsistent 
correlation, milder forms are difficult to diagnose. 
•Moderate DE:  
There is increase in intensity of symptoms, signs and visual effects are more 
apparent. 
•Severe DE:  
There is further increase in symptoms and visual disturbances are more 
disabling in severe forms 
28
 
 
 
21 
 
Table 1: DRY EYE SEVERITY GRADING
29
 
 
 
Dry eye severity 
level 
1 2 3 4* 
Discomfort, severity 
& frequency 
Mild and/or 
episodic; occurs 
under 
environmental 
stress 
Moderate 
episodic or 
chronic, 
stress or no 
stress 
Severe 
frequent or 
constant 
without stress 
Severe and/or 
disabling and 
constant 
Visual symptoms 
None or 
episodic mild 
fatigue 
Annoying 
and/or 
activity-
limiting 
episodic 
Annoying, 
chronic 
and/or 
constant, 
limiting 
activity 
Constant and/or 
possibly 
disabling 
Conjunctival 
injection 
None to mild 
None to 
mild 
+/- +/++ 
Conjunctivalstaining None to mild Variable 
Moderate to 
marked 
Marked 
Corneal staining 
(severity/location) 
None to mild Variable 
Moderate to 
marked 
Severe punctate 
erosions 
Corneal/tear signs None to mild 
Mild 
debris, ↑↓ 
meniscus 
Filamentary 
keratitis, 
mucus 
clumping, ↑ 
tear debris 
Filamentary 
keratitis, mucus 
clumping, ↑ tear 
debris, 
ulceration 
Lid/meibomian 
glands 
MGD variably 
present 
MGD 
variably 
present 
Frequent 
Trichiasis, 
keratinization, 
symblepharon 
TBUT (sec) Variable ≤10 ≤5 Immediate 
Schirmer score 
(mm/5 min) 
Variable ≤10 ≤5 ≤2 
 
*
 Must have signs AND symptoms. 
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Signs 
 Conjunctival injection,  
 Lid edema 
 Decreased tear meniscus,  
 Photophobia,  
 Increased tear debris,  
 Loss of corneal sheen found more commonly in the exposed 
interpalpebral fissure. 
 Disordered mucin production may lead to recurrent filamentary 
keratitis.  
 Neo vascularisation 
 Keratinization uncommonly in chronic DES and in vitamin A 
deficiency 
 Meibomian gland inspissations, glandular dropout (seen on trans 
illumination of the tarsus), chalazions, and eyelash debris are signs of 
meibomian gland disease and blepharitis. 
 Sterile ulceration of the cornea in Sjögren’s syndrome - can be 
peripheral or paracentral
29
; 
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DIAGNOSIS OF DRY EYE DISEASES 
Evaluation of a patient exhibiting dry eye symptoms includes  
 detailed patient history, 
 head to toe examination to look for signs of systemic diseases causing ocular 
surface diseases,  
 visual acquity and Fundus examination of the other eye 
 Slit lamp biomicroscopy of anterior segment and detailed examination of the 
ocular surface and adnexa. 
 Diagnostic tests. 
 
SLIT LAMP EVALUATION 
Following structures need to be examined in slit lamp 
 Eyelashes examination: may show, distichiasis, trichiasis, 
 Eyelid margin examination: 
o Meibomian gland abnormality & characteristics of meibomian gland 
secretions  
 Punctal examination: 
o Punctal patency and position 
 
24 
 
 Tear film examination: 
o Height of the meniscus, debris, mucus strands may be present 
 Conjunctiva: 
o Superior and Inferior fornix and tarsal conjunctiva examination:  
 stellate scar(healed trachoma),extensive scarring,  keratinization, 
fornix shortening, symblepharon. 
o Bulbar conjunctiva: e.g., punctate staining with ocular surface dye 
staining; follicles, hyperemia; localized drying, keratinization 
 Cornea: 
o Corneal staining with ocular surface dye staining in  punctate 
epithelial erosions, filamentary keratopathy, epithelial defects,  
o Keratinization, pannus formation, localized dellen, thinning, 
infiltrates, ulceration, scarring.
28
 
 
DIAGNOSTIC TESTS 
 
1. Tear break-up time (TBUT) test 
o Fluorescein strip moistened with saline and applied to the inferior tarsal 
conjunctiva. 
 
25 
 
Fig 11 
(Tear film break up viewed up with fluorescein stain on a patient with dry eye. Dry 
spots are indicated by the dark areas that appear on the cornea in the figure below) 
 
 
 
o Examination of the tear film is done with slit-lamp biomicroscope with a 
cobalt blue filter. 
o Interval between a complete blink and appearance of the first random dry 
spot is noted. 
o Break-up time of< 10 sec is abnormal. 
o A tear break-up time less than 10 sec may be seen ADDE and MGD.30 
26 
 
Ocular surface dye staining 
 Fluorescein dye test: 
o Fluorescein strips moistened with saline is used to stain the tear film. 
And then the ocular surface is examined through a Slit lamp using a 
cobalt blue filter. 
o When there is sufficient disruption of inter cellular junctions the dye 
permeates into the tissue of the corneal and conjunctival epithelia.
31
 
o Five areas in cornea are examined (central, superior, inferior nasal & 
temporal quadrant). Each area is given a score of 0-3. Hence maximum 
possible score is 15. 
o Punctate or blotchy fluorescein staining is seen in dry eye and staining is 
more apparent on the cornea than on the conjunctiva. 
Fig 12 
 
(Fluorescein dye staining of the cornea in a patient with dry eye disease, seen 
through the blue filter in Fig 12) 
27 
 
 1% Rose Bengal staining: 
o Debris in tear film takes up the stain. 
o Also it stains the cells without a mucous coating .30 
o Red-free filter is used to examine the cornea and conjunctiva 
o As per Van Bijsterveld three quadrants; nasal conjunctiva, temporal 
conjunctiva and cornea are examined and each area is graded 0 – 3 
according to the intensity of staining. 
o Out of total score of nine, more than four is considered abnormal. 
 
Fig 13 
 
 
(Temporal and nasal conjunctiva stained by Rose Bengal stain in dry eye is shown 
in Fig 13) 
28 
 
 Lissamine green dye: 
o It causes less irritation than Rose Bengal stain, but staining profile is 
similar.
32
 
o Lissamine green detects dead or degenerated cells. 
 
Fig 14 
(Lissamine green staining the bulbar conjunctiva is shown below) 
 
 
 
Interpretations of Ocular surface dye staining: 
 Diffuse staining pattern -viral keratoconjunctivitis, medicamentosa. 
 Inferior corneal & bulbar conjunctival staining -staphylococcal blepharitis, 
Meibomian Gland Dysfunction, lagophthalmos and exposure, 
29 
 
 Superior bulbar conjunctival staining -SLK.  
 Interpalpebral corneal and conjunctival staining -ADDE. 33, 34 
 
 
Schirmer Test 
 Aqueous tear production is assessed by Schirmer’s test. 
 It gives variable results. 
 It is performed by placing a Whatmann Filter paper No: 41 in the lateral 
aspect of lower fornix.  
 Schirmer’s test I 
o Done without anesthesia 
o Assesses both basal and reflex tear secretion. 
o More than10mm of strip wetting in 5 minutes is considered normal35 
 Schirmer’s test II 
o Done with topical anesthesia. Adequate time should be given after the 
drops to minimize reflex tearing. 
o Assesses the basal secretion of tears. 
       
 
 
30 
 
Fig 15 
(Schirmer’s test I is shown below) 
 
 
Table 2:  
 
 
31 
 
Evaluation of the tear prism. 
The tear meniscus height is assessed with slit lamp examination with or 
without fluorescein dye.
36
 
Height more than 0.2 millimeters (mm) is normal.
 
In aqueous tear deficiency 
there is scanty or absent tear meniscus. 
 
Fig 16 
(Tear meniscus height seen with Slit lamp) 
 
 
Tear-film debris. 
Debris and particulate matter in the tear film can be visualized by 
biomicroscopic examination. If present it denotes inadequate flushing due to 
reduced tear flow. 
32 
 
Phenol red thread test 
37 
Fig 17 
 
 
 Phenol red impregnated cotton is placed in lower lateral conjunctival fornix 
as shown above. 
  Phenol red is pH sensitive and changes from yellow to red when wetted by 
the tears. 
 Colour change will be seen after 15 sec 
 Wetting length should normally be between 9 mm to 20 mm. 
 
Other tests done for dry eye are  
 Evaluation of the pH  
 Evaluation of Lysozyme &Lactoferrin content of tears 
33 
 
 Tear osmolarity 
 Tear evaporation rate 
 Conjunctival biopsy and scraping 
 Impression cytology 
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TREATMENT 
 Treatment of the ocular surface disorder can be broadly divided into the 
treatment of primary disease causing disorder wherever applicable and treatment of 
ocular surface disease. Treatment of ocular surface disorder is summarized below. 
 
WARM COMPRESSES AND LID HYGIENE  
 Warm compresses are indicated in patients with meibomitis or meibomian 
gland dysfunction. The massaging action combined with heat helps express lipid 
into the tear film, preventing retention of lipid within the meibomian gland. 
Lid hygiene consists of cleansing the crust and scurf from the eye lashes 
with diluted baby shampoo
29
.  
 
TEAR SUPPLEMENTATION  
Artificial tear eye substitute is most commonly prescribed to treat all kinds 
of ocular surface disorders. But commercially available artificial tear substitutes do 
not include growth factors, vitamins, and immunoglobulins which are essential for 
maintaining the integrity and health of ocular surface.  
Artificial tear substitute often contain preservatives and additives, that are 
likely to elicit toxic or allergic reactions.
38
 
35 
 
 Hypotonic and electrolyte-balanced tear substitutes are preferable, and non 
preserved forms are recommended if tears are to be used more than four times a 
day. It minimizes the chances of toxicity to surface epithelial cells due to 
preservatives. 
AUTOLOGOUS SERUM DROPS 
 Recently autologous serum eye drops is routinely prescribed as an adjuvant 
therapy for the treatment ocular surface disorders, like dry eye disorders, 
neurotrophic keratitis, recurrent corneal erosion, persistent epithelial defects.
3
 
Human serum apart from providing lubrication, it contains substances such as 
EGF, vitamin A, TGF-β, fibronectin and interleukins, which are normally found in 
tears.  They are essential for corneal &conjunctival epithelial healing and 
integrity.
4 
 
It provides essential components of tears that are reduced in ocular surface 
disease
5
.Autologous serum, unlike artificial tear substitute does not elicit allergic 
reaction. 
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ANTI INFLAMMATORY THERAPY 
Cyclosporin A 
  Topical cyclosporin A, a fungal-derived molecule is indicated in 
moderate to severe aqueous insufficiency as a result of inflammation. 
Topical cyclosporin decreases ocular surface inflammation and results in an 
improvement in Schirmer’s test results and punctuates staining. 
Topical Corticosteroid  
  Low-dose corticosteroid therapy can be used at infrequent intervals 
for short-term (2 weeks) suppression of discomfort and epithelial disease 
secondary to inflammation.  
  Corticosteroids if used for long term may cause cataract and steroid 
response glaucoma. Hence it can’t be used for longer duration29. 
 
TETRACYCLINES  
Systemic tetracyclines (Doxycycline) are useful in treating posterior 
blepharitis or meibomitis with or without ocular rosacea.
39
 
37 
 
In addition to its antibacterial properties, tetracycline inhibits collagenase 
activity and decreases leukocyte chemotaxis and phagocytosis. 
 
SECRETOGOUGES 
 Cholinergic and muscarinic receptor agonists stimulate the secretion of 
mucin and tear secretion of goblet cells. 
 Oral pilocarpine 5-10 mg tablet twice daily is commonly prescribed. 
 
BANDAGE SOFT CONTACT LENS 
In recurrent filamentary keratopathy, soft contact lens is prescribed. But it is 
not prescribed in severe dry since it can exacerbate the dryness. Contact lenses 
should generally be avoided in neurotrophickeratopathy.40 
  
OMEGA-3 FATTY ACIDS  
A higher dietary intake of omega-3 an essential fatty acid, may decrease 
incidence of dry eye disease.
29 
 
 
38 
 
SURGICAL TREATMENT 
1. Punctal Occlusion  
  William Beetham introduced the use of punctal occlusion as a 
treatment for dry eye in 1935. 
  Punctal occlusion probably decreases tear film osmolarity by 
increasing the tear volume. It is useful in patients with aqueous tear 
deficiency, neurotrophic keratopathy and those with incomplete eyelid 
closure such as after blepharoplasty. 
 It may be  
a. temporary (absorbable collagen injection and plugs - gelatin) 
b. Reversible (Silicon – Acrylamide & Smart plug) 
c. Permanent (Thermal & electro cautery – Laser) 
2. Tarsorrhaphy  
  Tarsorrhaphy surgically decreases the interpalpebral surface area. It is 
used as a last resort in severe dry-eye disease, usually in the context of a 
persistent epithelial defect or corneal ulceration. 
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3. Other Surgical Procedures 
 Amniotic membrane grafting, 
 Conjunctival, limbal stem cell transplantation,  
 Parotid duct and salivary gland transplantation 
 Keratoprosthesis29 
 
TREATMENT RECOMMENDATIONS BY SEVERITY LEVEL 
 
Level 1: 
 Stopping of causative medications 
 Tear substitutes 
 Anti allergic topical drops 
 
Level II (In addition to Level I treatment) 
 Preservative free tear drops and gel 
 Oral and topical steroids 
 Immunosuppressive topical drugs 
 Secretagogues – Cholinergic receptor agonists 
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Level III (In addition to Level II treatment) 
 Autologous serum 
 Tetracyclines (Doxycycline) 
 Punctal occlusion (temporary, reversible or permanent)  
 
Level IV (In addition to Level III treatment) 
 Moisture goggles to prevent evaporation of tear 
 Contact lens 
 Surgical procedures29 
 
RECURRENT CORNEAL EROSION 
 Recurrent erosion of the corneal epithelium is a clinical syndrome of 
multiple etiologies, characterized by inadequate epithelial–stromal attachments, 
resulting in episodic dysadhesion and defects of the corneal epithelium. 
 Most common etiologies are trauma and epithelial basement membrane 
dystrophy. 
. Pathogenesis 
Normally, the corneal epithelium is firmly anchored to the Bowman layer 
and stroma by specialized attachment complexes. This epithelial basement 
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membrane complex is responsible for tight adhesion of the corneal epithelium to 
the stroma. Any traumatic, dystrophic, or degenerative process of the BM can 
result in defective epithelial adhesion and repetitive breakdown of the epithelial 
cell layer.
12
 
 
Fig 18 
 
Diagnosis 
 Patients present with symptoms of  
 Severe pain 
 Photophobia 
 Redness 
 Watering present on awaking in the morning 
 Prior H/O of corneal erosion 
 Recurrent symptoms 
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    Signs 
 Epithelial defect in inferior interpalpebral area,  
 It heals very rapidly but loosened epithelium will be seen on 
fluorescein examination. 
 
Treatment 
 Artificial tear drops  
 Antibiotic ointment 
 In severe cases bandage contact lens to alleviate the pain 
 Debridement of heaped epithelium by cellulose sponge may enhance 
healing. 
 5% NaCl drops and ointment improves epithelial adhesions 
 Following resolution lubricants can be used. 
 For recurrent symptoms long term extended wear bandage contact lens 
 Anterior stromal puncture reduces the recurrence rate.15 
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NEUROTROPHIC KERATITIS 
 
It is a corneal epithelial degenerative disease due to absence of corneal 
sensitivity, which is characterized by impaired healing. It may result in corneal 
stromal melting and perforation. 
 
Pathogenesis 
In neurotrophic keratopathy there is partial or complete anaesthesia due to 
loss of the trigeminal innervation to the cornea. 
The loss of neural influences results in intracellular oedema, exfoliation of 
epithelial cells, impairment of epithelial healing and loss of goblet cells, 
culminating in epithelial breakdown and persistent ulceration.
12 
 
 
Causes 
1. Acquired damage to the 5th cranial nerve or trigeminal ganglion due to surgical 
ablation, stroke, aneurysm or tumour (acoustic neuroma or neurofibroma). 
2.  Systemic disease such as diabetes and leprosy. 
3.  Ocular disease such as herpes simplex and herpes zoster keratitis,  
4.  Abuse of topical anaesthetic, 
5.  Chemical burn 
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6.  Refractive corneal surgery. 
7. Congenital causes like familial dysautonomia(Riley–Day syndrome) and 
hereditary sensory neuropathy 
15
 
 
Fig 19 
 
 
 
Clinical stages of neurotrophic keratitis
 
  Stage 1  
 Conjunctival staining by Rose Bengal,  Punctate epithelial staining 
with fluorescein   
 Accelerated TBUT   
 Dried epithelial spots 
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Stage II 
 Acute epithelial loss with surrounding rim of loose epithelium usually 
under the upper eyelid. 
 Smooth and rolled out ulcer margins 
 
Stage III 
 Stromal lysis, sometimes resulting in corneal perforation 
 
Diagnosis  
   
1     Corneal sensation is tested with a wisp of cotton or an anasthesiometer 
(<5 mm is clinically significant). 
   
2     Signs 
   •     Interpalpebral punctate keratopathy 
   •     Epithelial opacification, oedema and small defects. 
   
•     Persistent epithelial defect in which the epithelium at the edge of the 
lesion appears rolled and thickened, and is poorly attached. 
   •     Stromal corneal melting. 
   •     Perforation is uncommon, but occurs if there is secondary infection. 
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Treatment  
   1     Discontinuation of potentially toxic medications already in use. 
   
2     
3. 
Topical lubricant for associated dry eye or corneal exposure.  
Autologous serum containing insulin-like growth factor-1, substance P, and 
neurogenic growth factor can be used 
   
4     Protection of the ocular surface by the following:  
   
a     Simple taping of the lids, particularly at night, for temporary 
protection. 
   b     Botulinum toxin injection to induce a protective ptosis. 
   
c     Tarsorrhaphy may be temporary or permanent, and lateral or central, 
according to the underlying pathology. 
   d     Therapeutic silicone contact lenses 
   e     Amniotic membrane patch with temporary central tarsorrhaphy.
12
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AIMS AND OBJECTIVES 
 
AIM 
 To compare the efficacy of autologous serum ophthalmic solution versus 
tear drops as adjuvant therapy in the treatment of ocular surface diseases. 
 
PRIMARY OBJECTIVE: 
 To compare the efficacy of autologous serum ophthalmic solution versus 
tear drops as adjuvant therapy in the treatment of ocular surface diseases. 
 
SECONDARY OBJECTIVE: 
 1. To document prevalence of ocular surface diseases. 
2. To document the symptoms and clinical features of patients presented 
with ocular  surface diseases 
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MATERIALS & METHODS: 
 
   This prospective study was conducted at Cornea services department, 
RIOGOH, Madras Medical College, Egmore, Chennai-08, for a period of 6 
months.  
 
Methodology: 
 Patient presenting with ocular surface diseases to Cornea services 
department, RIOGOH was registered, evaluated and followed up during the study 
period. 
 
 A detailed history of the patient was taken, General Examination and Slit 
lamp examination, and dilated fundus examination were done. Relevant Laboratory 
and Radiological imaging were done and recorded. Patients fulfilling the inclusion 
criteria were sub classified into one of the three following categories and given a 
serial number. Sub classifications for ocular surface diseases were (1) Severe dry 
eye, (2) Neurotrophic Ulcer and (3) Recurrent corneal erosion. Following 
parameters were recorded on presentation; fluorescein staining, Rose Bengal 
staining, Tear break up time, Schirmer’s test. Patients will be treated as per the laid 
down guidelines. In addition patients with odd serial number in category will be 
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with autologous serum and patients with even serial number will be treated with 
tear drops. Symptom score and above mentioned parameters will be recorded 
during every follow-up. Treatment will be continued till symptoms disappear.  
 
PREPARATION OF SERUM  
 
 Around 30 ml of blood is extracted from patient’s vein without adding 
anticoagulant. The blood is kept in vertical position in tubes for about 2 hours to 
allow coagulation. Supernatant fluid is centrifuged to isolate the serum.  
 20% autologous serum is considered ideal because it contains certain growth 
factors at a concentration similar to that of natural tears
2
. Higher concentration is 
likely to cause irritation due to the higher viscosity. Also number of blood 
extraction is considerably reduced when used at lower concentration
4
.  
 Separated serum is labeled and preserved at 4
0
C. Once issued, patients are 
advised to preserve the serum in the refrigerator at +4°C after use
5
.  Autologous 
serum is protected from direct sun light to prevent degradation of some of the 
components like Vitamin A. 
 
SAMPLE SIZE: 30 patients 
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INCLUSION CRITERIA: 
 1.  Age 15- 70 years 
 2.  Patients with ocular surface diseases due to 
      a. Severe dry eye 
      b. Neurotrophic ulcer 
      c. Recurrent corneal erosion 
 
EXCLUSION CRITERIA: 
1. Patients with Infectious blood borne diseases (HIV, HBV, HCV and  
Syphilis) 
2. Patients with Anaemia and known blood dyscrasias.  
3. Women who are pregnant or breast-feeding.  
4. Patients unable to provide informed consent. 
 
SCREENING PROCEDURES: 
1. Detailed history of present illness,  
2. Ocular symptoms on presentation 
3. Signs on presentation 
4. Visual acuity using Snellen’s acuity chart 
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5. Slit lamp biomicroscopy of anterior segment 
6. Fundus Examination of the same and other eye 
7. Laboratory Investigations 
8. Fluorescein staining, Rose Bengal staining,  
9. Tear break up time,  
10. Schirmer’s test 1 & 2 
 
FOLLOW UP PROCEDURES / VISITS: 
 Weekly in the 1
st 
first month and twice weekly in the 2
nd
 month. 
 
ASSESSMENTS OF PARAMETERS: 
 1. Symptoms and signs on presentation and follow up. 
 2. Slit lamp examination 
 3. Tear breakup time 
 4. Schirmer’s test 
 5. Rose Bengal Staining 
 6. Fluorescin staining 
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RESULTS AND ANALYSIS 
Results of the patients were analyzed for statistical significance with unpaired and 
chi Squared test. 
AGE 
Age distribution of the patients involved in the study is depicted below.  
Table 3: 
Age 
Distribution 
Autologous 
Serum 
% 
Tear 
Substitute 
% 
≤ 20 years 1 6.67 2 13.33 
21-40 years 8 53.33 5 33.33 
41-60 years 4 26.67 6 40.00 
61-70 years 2 13.33 2 13.33 
Total 15 100 15 100 
 
Mean age of the patients is 40.5 yrs and mean age of the patients in group 1 is 39.8 
yrs and group 2 is 41.87 yrs. 
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Fig 20 
 
Age distribution is depicted in Bar chart (Fig 20, Tables 4 & 5) 
Table 4:   
Table 4 shows mean age and standard deviation in Group I and II 
Age Distribution Autologous Serum Tear Substitute 
N 15 15 
Mean 39.60 41.47 
SD 16.87 17.63 
P value Unpaired t Test 0.7692 
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GENDER STATUS 
 There were 8 males and 7 females in Group 1 and 9 males and 6 females in 
Group 2 as shown in Fig 21 and Table 5. 
Fig 21 
 
Table 5: 
Gender 
Status 
Autologous 
Serum 
% 
Tear 
Substitute 
% 
Male 8 53.33 9 60.00 
Female 7 46.67 6 40.00 
Total 15 100 15 100 
P value 
Chi Squared Test 
0.7126 
Autologous Serum
Tear Substitute
0
5
10
Male
Female
8 
7 
9 
6 
Autologous Serum Tear Substitute
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 CAUSATIVE FACTORS IN THIS STUDY 
 Various causative factors for the Ocular surface disorder in this study are 
depicted below. Sjögren’s syndrome (34%) is the most common cause in our 
study, followed by Steven Johnson’s (20%). Neurotrophic keratitis is the causative 
factor for Ocular surface disorder in 13% of study population and Meibomian 
gland dysfunction also occurred in 13% of study population. 
Fig 22 
 
 
SYMPTOM SCORE 
Results of each symptom score comparison is described below. 
34% 
20% 
13% 
13% 
10% 
7% 
3% 
CAUSATIVE FACTORS IN THIS STUDY 
Sjogren's Syndrome
Stephen Johnson's syndrome
Neurotrophic Keratitis
Meibomian Gland Dysfunction
Recurrent corneal erosion
(unknown)
Recurrent corneal erosion
(trauma)
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1. TEARING 
Fig 23 
 
Table 6: 
Tearing 1st Visit 2nd Visit 3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 21 21 21 21 15 10 
Mean 1.90 1.71 1.43 1.19 1.00 1.00 
SD 1.00 0.85 0.51 0.40 0.00 0.00 
Tear Substitute 
N 23 23 21 18 17 9 
Mean 1.48 1.43 1.38 1.33 1.12 1.11 
SD 0.85 0.84 0.67 0.59 0.33 0.33 
P value  
Unpaired t Test 
0.1320 0.2790 0.7962 0.3792 0.1811 0.3051 
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 There is no significant difference in the improvement of symptom score 
between autologous serum and Artificial tear substitute during the follow up period 
as shown above in bar chart and table. 
2. BURNING 
Fig 24 
 
 
 There was significant difference in improvement of the burning sensation of 
patients treated with autologous serum during 3
rd
, 4
th
 and 5
th
 and 6
th
 visit as shown 
above in Fig 24 and Table 7 below. 
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Table 7: 
Burning 1st Visit 2nd Visit 3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 20 20 20 20 15 10 
Mean 2.75 2.75 2.05 1.75 1.67 1.50 
SD 1.02 1.02 1.00 0.79 0.82 0.71 
Tear Substitute 
N 23 23 21 18 17 10 
Mean 2.91 2.87 2.71 2.67 2.47 2.60 
SD 0.85 0.92 0.90 0.84 0.80 0.70 
P value  
Unpaired t Test 
0.5701 0.6881 0.0311 0.0014 0.0086 0.0026 
 
3. FB SENSATION 
Fig 25 
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Table 8: 
FB Sensation 1st Visit 2nd Visit 3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 21 21 21 21 15 10 
Mean 2.76 2.48 2.05 1.76 1.87 1.50 
SD 0.94 0.98 0.97 0.83 0.83 0.53 
Tear Substitute 
N 23 23 20 18 17 9 
Mean 2.83 2.83 2.80 2.67 2.41 2.67 
SD 0.72 0.72 0.89 0.91 0.71 0.50 
P value  
Unpaired t Test 
0.7997 0.1813 0.0140 0.0025 0.0552 0.0001 
 
 There was significant difference in improvement of the foreign body 
sensation in patients treated with autologous serum during 3
rd
 4
th
 and 6
th
 visit.  
 
4. PHOTOBHOBIA 
 There is significant difference in improvement of the photophobia of the 
patients treated with autologous serum during 3
rd
 visit, 4
th
 visit, 5
th
 visit and 6
th
 visit 
as shown in Fig 26 and Table 9 below. 
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Fig 26 
 
Table 9 
Photophobia 1st Visit 
2nd 
Visit 
3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 21 21 21 21 15 10 
Mean 2.86 2.62 1.81 1.57 1.60 1.30 
SD 0.85 0.97 0.98 0.75 0.83 0.67 
Tear Substitute 
N 23 23 21 18 17 9 
Mean 2.74 2.70 2.67 2.50 2.24 2.78 
SD 0.81 0.82 0.86 0.86 0.90 0.83 
P value  
Unpaired t Test 
0.6404 0.7787 0.0044 0.0009 0.0478 0.0005 
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5. BLURRED VISION 
Fig 27 
 
Table 10: 
Blurred Vision 1st Visit 2nd Visit 3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 21 21 21 21 15 10 
Mean 3.38 3.14 2.95 2.86 3.07 3.00 
SD 0.86 0.96 1.16 1.11 0.88 1.15 
Tear Substitute 
N 23 23 21 18 17 9 
Mean 3.39 3.39 3.43 3.44 3.35 3.67 
SD 0.78 0.78 0.81 0.78 0.86 0.50 
P value  
Unpaired t Test 
0.9669 0.3514 0.1311 0.0681 0.3615 0.1283 
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 There is no significant difference in improvement in blurred vision of the 
patients treated with autologous serum. 
 
6. DIFFICULTY IN OPENING EYELIDS 
Fig 28 
 
 
 There is earlier significant improvement in difficulty in opening eyelids (1
st
 
visit) in patients treated with autologous serum as shown above (p value 0.0081). 
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Table 11: 
Difficulty in Opening Eyelids 1st Visit 2nd Visit 3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 21 21 20 21 15 10 
Mean 3.00 2.57 2.10 1.76 1.73 1.40 
SD 0.89 0.87 0.91 0.77 0.80 0.70 
Tear Substitute 
N 23 23 21 18 17 9 
Mean 2.30 2.30 2.29 1.94 1.76 1.78 
SD 0.76 0.76 0.85 0.73 0.56 0.44 
P value  
Unpaired t Test 
0.0081 0.2848 0.5026 0.4528 0.8977 0.1827 
 
7. STINGY DISCHARGE 
Fig 29 
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Table 12: 
Stingy Discharge 1st Visit 2nd Visit 3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 20 20 20 20 15 11 
Mean 1.40 1.35 1.30 1.15 1.13 1.09 
SD 0.75 0.75 0.73 0.49 0.52 0.30 
Tear Substitute 
N 21 21 19 18 17 9 
Mean 1.24 1.24 1.26 1.22 1.24 1.44 
SD 0.70 0.70 0.73 0.55 0.56 0.73 
P value  
Unpaired t Test 
0.4802 0.6229 0.8762 0.6704 0.5989 0.1580 
 
 There is no significant difference in improvement between the patients 
treated with autologous serum and artificial tear substitute.  
 
SIGN SCORES 
    1. LID EDEMA 
            There is no significant difference in improvement of lid edema in between          
Group 1 and 2 as shown below. 
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Fig 30 
 
 
Table 13: 
LID EDEMA 1st Visit 2nd Visit 3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 21 21 21 21 15 10 
Mean 2.19 2.10 2.05 1.76 2.07 2.00 
SD 0.81 0.77 0.80 0.94 0.96 0.94 
Tear Substitute 
N 23 22 21 18 17 11 
Mean 2.04 2.05 2.05 2.00 1.94 2.09 
SD 0.82 0.84 0.86 0.91 0.97 0.94 
P value  
Unpaired t Test 
0.5554 0.8409 1.0000 0.4291 0.7158 0.8278 
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2. CONJUNCTIVAL CONGESTION 
Fig 31 
 
Table 14: 
Conjunctival Congestion 
1st 
Visit 
2nd 
Visit 
3rd 
Visit 
4th 
Visit 
5th 
visit 
6th 
visit 
Autologous 
Serum 
N 21 21 21 21 15 10 
Mean 2.19 1.81 1.33 1.14 1.20 1.20 
SD 0.51 0.60 0.58 0.36 0.41 0.42 
Tear 
Substitute 
N 23 23 21 18 17 11 
Mean 2.22 2.13 1.71 1.67 1.35 1.27 
SD 0.42 0.55 0.64 0.59 0.49 0.47 
P value  
Unpaired t Test 
0.8494 0.0711 0.0502 0.0017 0.3530 0.7132 
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 There was no significant difference in improvement of conjunctival 
congestion during first, second and third visit but there was significant difference 
in improvement of conjunctival congestion during the fourth visit and there was no 
significant improvement in symptoms during 5
th
 and 6
th
 visit. 
 
3. EPITHELIAL DEFECT 
 There was no significant difference in improvement of epithelial defect 
during 1
st
, 2
nd
, 3
rd
 visit. There was significant difference during 4
th
 and 5
th
 visit as 
shown below 
Fig 32 
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Table 15: 
Epithelial Defect 1st Visit 
2nd 
Visit 
3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 21 21 21 21 15 10 
Mean 2.10 2.05 1.81 1.33 1.13 1.10 
SD 0.62 0.59 0.68 0.48 0.35 0.32 
Tear Substitute 
N 23 23 21 18 17 11 
Mean 2.17 2.09 2.05 1.78 1.47 1.45 
SD 0.39 0.51 0.50 0.65 0.51 0.52 
P value  
Unpaired t Test 
0.6150 0.8144 0.2026 0.0190 0.0411 0.0789 
 
 
4. NEOVASCULARISATION  
 There is no significant difference in improvement of neovascularisation 
between Groups 1 & 2 as depicted below in Fig 33 and Table 16. 
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Fig 33 
 
Table 16: 
Neovascularisation 1st Visit 
2nd 
Visit 
3rd 
Visit 
4th 
Visit 
5th visit 6th visit 
Autologous 
Serum 
N 21 21 21 21 15 10 
Mean 2.00 2.00 2.00 1.95 2.20 2.20 
SD 0.95 0.95 0.95 0.97 1.01 1.03 
Tear Substitute 
N 23 22 21 18 17 11 
Mean 2.09 2.05 2.10 2.06 2.12 2.27 
SD 0.79 0.79 0.83 0.87 0.86 0.79 
P value  
Unpaired t Test 
0.7423 0.8647 0.7311 0.7313 0.8051 0.8570 
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5. SCHIRMER’S TEST 
Fig 34 
 
Table 17: 
Schirmer’s test 1st Visit 2nd Visit 3rd Visit 4th Visit 5th visit 6th visit 
Autologous 
Serum 
N 21 21 21 21 15 10 
Mean 1.95 1.57 1.14 1.00 1.00 1.00 
SD 0.38 0.51 0.36 0.00 0.00 0.00 
Tear Substitute 
N 23 23 21 18 17 11 
Mean 1.70 1.65 1.48 1.39 1.06 1.00 
SD 0.56 0.57 0.60 0.50 0.24 0.00 
P value Unpaired t Test 0.0859 0.6245 0.0351 0.0010 0.3560 >0.9999 
 
 There is significant difference in improvement of Schirmer’s  paper 
wetting in patients treated with autologous serum during 3
rd
 and 4
th
 visit. 
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 Comparison of symptoms score between Group 1 (autologous serum) 
with group 2 (artificial tear substitute) along with p value is tabulated below 
Table 18: 
Symptoms P value Significance 
1
st
 
visit 
2
nd
 
visit 
3
rd
 
visit 
4
th
 
visit 
5
th
 
visit 
6
th
 
visit 
Tearing 0.1320 0.2790 0.7962 0.3792 0.1811 0.3051 No 
significant 
difference 
Burning 0.5701 0.6881 0.0311 0.0014 0.0086 0.0026 Significant 
difference in 
3
rd
 -6
th 
visit 
FB 
Sensation 
0.7997 0.1813 0.0140 0.0025 0.0552 0.0001 Significant 
difference in 
3, 4
th
& 6
th
 
Photophobia 0.6404 0.7787 0.0044 0.0009 0.0478 0.0005 Significant 
difference in 
3-6
th
 
Blurred 
vision 
0.9669 0.3514 0.1311 0.0681 0.3615 0.1283 No 
significant 
difference 
Difficulty in 
opening eye 
lids 
0.0081 0.2848 0.5026 0.4528 0.8977 0.1827 Significant 
difference in 
1st 
 
 Comparison of improvement in signs between Group 1 (autologous 
serum) with group 2 (artificial tear substitute) along with p value is tabulated 
below  
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Table 19: 
Signs P value Significan
ce 1
st
 visit 2
nd
 
visit 
3
rd
 
visit 
4
th
 
visit 
5
th
 
visit 
6
th
 visit 
Lid edema 
0.5554 0.8409 1.0000 0.4291 0.7158 0.8278 
No 
significant 
difference 
Circum 
corneal 
congestion 
0.8494 0.0711 0.0502 0.0017 0.3530 0.7132 
Significant 
difference 
in 4
th
 
Epithelial 
defect 0.6150 0.8144 0.2026 0.0190 0.0411 0.0789 
Significant 
difference 
in 4
th
& 5
th
 
Neovascula
risation  0.7423 0.8647 0.7311 0.7313 0.8051 0.8570 
No 
significant 
difference 
Schirmer’s 
1&2 0.0859 0.6245 0.0351 0.0010 0.3560 >0.999 
Significant 
difference 
in 3
rd
 – 4th 
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CASE PROFILE PICTURES 
 
Case I: 24 yr female, a case of Sjögren's syndrome treated with autologous 
serum 
Fig 35 
Pre treatment Post treatment 
 
 
 
 
Epithelial defect  + 
Schirmer’s 1 & 2 < 10mm  
Epithelial defect  healed, in 1 month       
and Schirmer’s 1 & 2 > 10mm  
 
 
 
 
74 
 
Case 2: 35 yr Female, a case of recurrent corneal erosion treated with 
autologous serum. Pre and post treatment pictures are shown below in Fig 36. 
 
Fig 36: 
Pre treatment Post treatment 
 
 
 
 
Epithelial defect  + Epithelial defect  healed within 2 weeks 
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Case 3: 56 yr Female, a case of Sjögren's syndrome treated with Artificial tear 
substitute.  
Fig 37 
Pre Treatment Post Treatment 
 
 
 
  
 
Schirmer’s 1&2 < 5 mm.  Schirmer’s 1 & 2 mm < 5mm,   
in 1 month 
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DISCUSSION 
AGE DISTRIBUTION 
 In this study 80% population in Group I (Autologous serum) and 73.33% of 
population in Group II (Artificial tear substitute) were between 20 to 40 yrs. Mean 
age of the patient is 40.5 years  
 Dry eye syndrome affects 10-30% of the population older than forty years in 
United States as per the report of Epidemiology Subcommittee of the International 
Dry Eye Workshop. Nurses’ Health Study (Schaumberg et al) shows prevalence of 
5.7% less than 50years and 9.8% in more than 75 yrs old. 
 In our study, the upper age limit of the patient is 70 yrs and there were 
stringent exclusion criteria so as to use autologous serum. Hence there is a trend 
towards lower age distribution in our study than in the published literature. 
GENDER STATUS 
 Ocular surface disorder is slightly more common in women. This may be 
due to the fact that 90% of the patients affected with Dry Eye Syndrome due to 
Sjögren’s syndrome are women.   
 In our study out of 30 patients there were 17 males and 13 females. The 
difference may partly be explained by different causative factors included in the 
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study like meibomian gland dysfunction, trauma, herpes etc. Also the women with 
anemia, pregnant and lactating women are excluded study which may also 
contribute to the discrepancy. 
SYMPTOM SCORES 
 In our study improvement in symptom scores of the patients treated with 
autologous serum (Group I) is compared with the symptom score of the patients 
treated with Artificial tear substitute (Group II) during each visit.  
 In our study there is improvement in tearing, blurred vision and stingy 
discharge in both the groups. How ever there is no significant difference in 
improvement between both the groups. Finding implies that both autologous serum 
and artificial tear substitute are equally effective in stopping the tearing, 
improvement of blurring vision and stingy discharge during the follow up period. 
 In a study by Tanauvat et al in 12 patients treated with autologous serum 
there was improvement in symptoms and signs of dry eye but was not statistically 
significant. Similarly in our study there was no statistically significant difference in 
improvement of above mentioned symptoms.
40
 
 In this study there is significant difference in improvement of burning 
sensation in patients treated with autologous serum during 3
rd
 (p= 0.0311), 4
th
 
(p=0.0014), 5
th
 (p=0.0086) and 6
th
 (0.0026) visit.  There is significant difference in 
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improvement of Foreign body sensation in patients treated with autologous serum 
during 3
rd
 (p=0.0140), 4
th
 (p=0.0025) and 6
th
 visit (p=0.0001). There is significant 
difference in improvement of the photophobia of the patients treated with 
autologous serum during 3
rd
 visit (p=0.0044), 4
th
 visit (p=0.0009), 5
th
 visit 
(p=0.0478) and 6
th
 visit (p=0.0005). There is also earlier significant improvement 
in difficulty in opening eyelids (1
st
 visit) in patients treated with autologous serum 
(p value 0.0081). 
 Kojima et al conducted study on effectiveness of the 20% autologous serum 
Vs preservative free artificial tear drops for severe dry eye disease. There is 
significant improvement in the mean break-up time and staining scores of the 
patients treated with autologous serum. There was also significant improvement in 
subjective symptoms scores, in patients treated with autologous serum when 
compared with patients treated with preservative-free artificial tears.
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SIGN SCORES 
 In our study there is no significant difference in improvement of lid edema 
in between Group 1 and 2. There is also no significant difference in improvement 
of neovascularisation between the groups. In a study by Noble et al in 6 patients of 
Sjogren’s syndrome and 5 patients of kerato conjunctivitis sicca, there was no 
significant improvement in Rose Bengal staining, Schirmer’s test and  tear 
clearance test.
42
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 There was significant difference in improvement of epithelial defect during 
4
th
 (p=0.0190) and 5
th
 visit (p=0.0411). There is significant difference in 
improvement of Schirmer’s paper wetting in patients treated with autologous 
serum during 3
rd
 (p value 0.0351) and 4
th
 visit (0.0010).Tsubota et al study on 
effect of autologous serum on persistent epithelial corneal defect showed that the 
serum was effective in more than 60% of patients.
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 Del Castillo et al studied the effect of 20% autologous serum in recurrent 
corneal erosions. He concluded that the autologous serum appears to be safe and 
effective in preventing the number of recurrences.
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 Matsumoto et al conducted study on neurotrophic keratitis in 14 eyes of 11 
patients and found that the epithelial defect healed completely in all eyes within 6 
to 32 days. There was reduction in corneal scarring. Study concluded that 
neurotrophic factors in autologous serum may provide neurologic healers for the 
compromised ocular surface. 
COMPLICATIONS 
 In our study there were no complications with the use of autologous serum 
and artificial tear substitute. 
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CONCLUSION 
 Autologous serum is found to be safe and significantly effective than the 
artificial tear substitute in the treatment of ocular surface disorders. 
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LIMITATIONS OF THE STUDY 
 Incidence and prevalence 
 The study was not designed to bring out the incidence and prevalence 
of the ocular surface disorders because of the age criteria and exclusion 
criteria. 
 Preparation and distribution 
 Preparation of autologous serum can be done in tertiary care institute 
with facility for withdrawing blood in adequate quality and preparation of 
serum. This procedure may not be feasible other set ups. Autologous serum 
need to be stored at 4
0
C and issued in sterile container. 
 Duration of treatment 
 In Chronic Inflammatory disorders like Sjögren’s syndrome the serum 
may need to be used for a prolonged period. Hence frequent withdrawal of 
blood to harvest autologous serum may not be feasible. 
 Contamination 
 There is risk of contamination during extraction, storage and use. 
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 Recurrence of symptoms 
 The study followed the patients till the continuation of treatment, so 
recurrence of symptoms and signs on stopping the treatment could not be 
commented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
PART III 
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ABBREVIATIONS  
 
1.  EGF EPIDERMAL GROWTH FACTOR 
2.  TGF-B TRANSFORMING GROWTH FACTOR-B 
3.  SSDE SJOGREN SYNDROME DRY EYE 
4.  Non SSDE NON SJOGREN’S SYNFROME DRY EYE 
5.  ANA ANTI NUCLEAR ANTIBODY 
6.  SS-A SJOGREN SYNDROME –RELATED ANTIGEN A 
7.  SS-B SJOGREN SYNDROME -RELATED ANTIGEN B 
8.  DE DRY EYE 
9.  TBUT TEAR BREAK UP TIME 
10. MGD MEIBOMIAN GLAND DISEASE 
11. DES DRY EYE SYNDROME 
12. ADDE AQUEOUS DEFICIENT DRY EYE 
13. SLK SUPERIOR LIMBIC KERATOCONJUNCTIVITIS 
14. HIV HUMAN IUMMUNO DEFICIENCY VIRUS 
15. HBV HEPATITIS B VIRUS 
16. HCV HEPATITIS C VIRUS 
17. HB HAEMOGLOBIN 
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18. ESR ERYTHROCYTE SEDIMENTATION RATE 
19. P,L,M,B,E 
POLYMORPHONUCLEAR LEUKOCYTES , 
LYMPHOCYTES, MONOCYTES, BASOPHILS, 
EOSINOPHIL. 
20. VDRL 
VENERAL DISEASE RESEARCH 
LABORATORY 
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PROFORMA 
Sl.No: OP/IP No Sub Category: 
Name: Age: Sex:  
 
SYMPTOMS  
GRADE 1 TO 4 
  
 Grade 1 - no symptom 
 Grade 2 - Slight 
 Grade 3 - Moderate 
 Grade 4 - Severe 
Symptoms 1
st
 Visit 2
nd
 visit 3
rd
 visit 4
th
 visit 5
th
 visit 6
th
 visit 
 Rt  Lt Rt Lt Rt Lt Rt Lt Rt Lt Rt Lt 
Tearing             
Burning             
Foreign Body Sensation             
Photophobia             
Blurred vision             
Difficulty in opening eyelids             
Stringy discharge             
 
SIGNS 
GRADE 1 TO 3 
Grade 1 - absence of signs 
Grade 2 - slight 
Grade 3 - severe 
 
Signs  1
st
 Visit 2
nd
 visit 3
rd
 visit 4
th
 visit 5
th
 visit 6
th
 visit 
 Rt  Lt Rt Lt Rt Lt Rt Lt Rt Lt Rt Lt 
Lid edema             
Conjunctival congestion             
Slit lamp examination             
Epithelial defect Fluorescein             
Epithelial defect Rose Bengal             
Neovascularisation             
Shirmer’s test             
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Laboratory Investigations 
 On Presentation 
Total Count  
Differential Count P      L     M     B     
E 
Hb  
ESR  
HIV (Card/ELISA)  
HBV (HBsAg)  
HCV (Anti HCV)  
Syphilis (VDRL)  
 
Treatment Given  
Drug Name 1
st
 Visit 2
nd
 Visit 3
rd
 Visit 4
th
 Visit 5
th
 Visit 6
th
 Visit 
Date             
Side             
 
 
 
 
            
 
 
 
 
            
 
 
 
 
            
 
 
 
 
            
 
 
 
 
            
 
 
 
